DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer

Journal of Immunotherapy

Volumn 33, Issue 6, 2010, Pages 639-647

  Becker, Jordan T ^a   Olson, Brian M ^a   Johnson, Laura E ^a   Davies, James G ^a   Dunphy, Edward J ^a   McNeel, Douglas G ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Clinical trial; DNA vaccine; Prostate cancer; Prostatic acid phosphatase; T cell immune response monitoring

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; DNA VACCINE; GAMMA INTERFERON; HLA A2 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ARTICLE; CANCER IMMUNIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; INTERFERON PRODUCTION; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT CANCER; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; CANCER VACCINES; CELL PROLIFERATION; CELLS, CULTURED; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 77954951895     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181dda23e     Document Type: Article

References (26)

1. Meidenbauer N, Harris DT, Spitler LE, et al. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate. 2000;43:88-100.
2. Perambakam S, Hallmeyer S, Reddy S, et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol Immunother. 2006;55:1033-1042.
3. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 2000;6:1632-1638.
4. Gulley J, Chen AP, Dahut W, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate. 2002;53:109-117.
5. Pavlenko M, Roos AK, Lundqvist A, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer. 2004;91:688-694.
6. Fong L, Brockstedt D, Benike C, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol. 2001;167:7150-7156.
7. Small EJ, Schellhammer PF, Higano CS, et al. Placebocontrolled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089-3094.
8. Mincheff M, Tchakarov S, Zoubak S, et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol. 2000;38:208-217.
9. Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostatespecific membrane antigen. Prostate. 1996;29:371-380.
10. Wolchok JD, Gregor PD, Nordquist LT, et al. DNA vaccines: an active immunization strategy for prostate cancer. Semin Oncol. 2003;30:659-666.
11. Slovin SF, Scher HI. Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man-clinical trials at Memorial Sloan-Kettering Cancer Center. Semin Oncol. 1999;26:448-454.
12. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323-5337.
13. Murphy GP, Tjoa BA, Simmons SJ, et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate. 1999;39:54-59.
14. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894-3903.
15. Small EJ, Schellhammer PF, Higano CS, et al. Results of a placebo-controlled phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol. 2005;23:4500.
16. Johnson LE, Frye TP, Arnot AR, et al. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine. 2006;24:293-303.
17. + T cells. Cancer Immunol Immunother. 2007;56:885-895.
18. Gnjatic S, Altorki NK, Tang DN, et al. NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res. 2009;15:2130-2139.
19. Tagawa ST, Lee P, Snively J, et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer. 2003;98:144-154.
20. Conry RM, Curiel DT, Strong TV, et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res. 2002;8:2782-2787.
21. McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol. 2009;27:4047-4054.
22. Olson BM, Frye TP, Johnson LE, et al. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother. 2010;59:943-953.
23. Lacelle MG, Jensen SM, Fox BA. Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res. 2009;15:6881-6890.
24. Ferrera F, La Cava A, Rizzi M, et al. Gene vaccination for the induction of immune tolerance. Ann N Y Acad Sci. 2007;1110:99-111.
25. Garren H, Robinson WH, Krasulova E, et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol. 2008;63:611-620.
26. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670-3679.